JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cowan, W K
Right arrow Articles by Al-Tamimi, S R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cowan, W K
Right arrow Articles by Al-Tamimi, S R.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Breast Cancer
J Clin Pathol 2000; 53:140-146
© 2000 Journal of Clinical Pathology

A study of interval breast cancer within the NHS breast screening programme

W K Cowan1, B Angus2, J C Gray3, L G Lunt1, S Ramedan Al-Tamimi2

1 Breast Unit, Queen Elizabeth Hospital, Gateshead NE9 6SX, UK
2 Department of Pathology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK
3 Centre for Health and Medical Research, University of Teesside, Middlesbrough TS1 3BA, UK

Dr Angus email: brian.angus{at}ncl.ac.uk Aim—To define the biological nature and malignant potential of interval cancers presenting to a breast unit within the NHS breast screening programme.

Methods—112 interval cancers were compared with matched, screen detected and symptomatic cancers in terms of their radiographic, histopathological, and immunohistochemical features.

Results—Interval cancers, strictly defined, showed no characteristic radiographic pattern. In terms of size, vascular invasion, lymph node status, and prognosis they were intermediate between screen detected and symptomatic cancers. Within the interval cancers there was an excess of grade 1 and grade 3 tumours, and lesions with a high Ki67 index but immunohistochemistry otherwise failed to discriminate between the three groups. Inclusion of data from false negative "interval cancers" did not significantly alter the results.

Conclusions—Interval cancers are more aggressive than screen detected cancers but in general less aggressive than symptomatic cancers. However, within a heterogeneous group, occasional interval cancers are exceptionally malignant.

Key Words: breast cancer screening • interval cancer




This article has been cited by other articles:


Home page
Ann Fam MedHome page
P. A. Carney, E. Steiner, M. E. Goodrich, A. J. Dietrich, C. J. Kasales, J. E. Weiss, and T. MacKenzie
Discovery of Breast Cancers Within 1 Year of a Normal Screening Mammogram: How Are They Found?
Ann. Fam. Med, November 1, 2006; 4(6): 512 - 518.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Collett, I. M. Stefansson, J. Eide, A. Braaten, H. Wang, G. E. Eide, S. O. Thoresen, W. D. Foulkes, and L. A. Akslen
A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1108 - 1112.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
P J van Diest, E van der Wall, and J P A Baak
Prognostic value of proliferation in invasive breast cancer: a review
J. Clin. Pathol., July 1, 2004; 57(7): 675 - 681.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
T J Anderson, C Davis, F E Alexander, and H M Dobson
Measures of benefit for breast screening from the pathology database for Scotland, 1991-2001
J. Clin. Pathol., September 1, 2003; 56(9): 654 - 659.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.